Inhalerx Ltd - Asset Resilience Ratio

Latest as of June 2023: 46.96%

Inhalerx Ltd (IRX) has an Asset Resilience Ratio of 46.96% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read IRX current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

AU$525.99K

≈ $372.17K USD Cash + Short-term Investments

Total Assets

AU$1.12 Million

≈ $792.60K USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2022)

This chart shows how Inhalerx Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Inhalerx Ltd for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Inhalerx Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IRX company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$525.99K	46.96%
Short-term Investments	AU$0.00	0%
Total Liquid Assets	AU$525.99K	46.96%

Asset Resilience Insights

Very High Liquidity: Inhalerx Ltd maintains exceptional liquid asset reserves at 46.96% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Inhalerx Ltd Industry Peers by Asset Resilience Ratio

Compare Inhalerx Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Ascendis Pharma AS F:A71	Biotechnology	0.00%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	1.39%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
R&G PharmaStudies Co. Ltd. A SHE:301333	Biotechnology	35.96%
Shanghai Shen Lian Biomedical Corp SHG:688098	Biotechnology	3.87%

Annual Asset Resilience Ratio for Inhalerx Ltd (2016–2022)

The table below shows the annual Asset Resilience Ratio data for Inhalerx Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	94.48%	AU$2.13 Million ≈ $1.51 Million	AU$2.26 Million ≈ $1.60 Million	-1.17pp
2021-12-31	95.64%	AU$2.80 Million ≈ $1.98 Million	AU$2.93 Million ≈ $2.07 Million	+5.34pp
2020-12-31	90.31%	AU$1.72 Million ≈ $1.22 Million	AU$1.90 Million ≈ $1.35 Million	+15.43pp
2018-12-31	74.88%	AU$2.31 Million ≈ $1.64 Million	AU$3.09 Million ≈ $2.19 Million	-13.91pp
2017-12-31	88.79%	AU$4.52 Million ≈ $3.20 Million	AU$5.09 Million ≈ $3.60 Million	+0.04pp
2016-12-31	88.75%	AU$7.61 Million ≈ $5.38 Million	AU$8.58 Million ≈ $6.07 Million	--

pp = percentage points

About Inhalerx Ltd

AU:IRX Australia Biotechnology

Market Cap

$4.18 Million

AU$5.91 Million AUD

Market Cap Rank

#28669 Global

#1620 in Australia

Share Price

AU$0.02

Change (1 day)

+4.35%

52-Week Range

AU$0.02 - AU$0.05

All Time High

AU$0.39